Cleerly, a cardiovascular AI imaging company, has announced its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) to be held between March 29-31, 2025. It is to be held at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share about its findings about Artificial Intelligence-based Quantitative Computed Tomography (AI-QCT) and its role in identifying risks of future major adverse cardiovascular events (MACE) in women. At the location, Cleerly will demonstrate the company’s AI-enabled coronary computed tomography angiography (CCTA) solution that would help guide personalized prognosis, diagnosis, and treatment of coronary artery disease (CAD).
Dr. James Min, the founder and CEO of Cleerly, will be a featured speaker on the Health Equity Panel on March 30th. The session, “Championing Communities of Health: A Cross-Industry Panel Discussion on Community Education, Cardiovascular Disease Prevention, and Screening Programs,” will tackle important topics around health equity and community involvement in cardiovascular health. Cleerly will also host a Lounge & Learn Session, “Increasing Female Physician Leadership in Clinical Trials,” on March 30th from 1:00 to 1:30 PM in the Education Zone, Theater 1 of the Lounge and Learn Pavilion. In addition, Cleerly will present six abstracts highlighting advancements in heart health technology and research throughout the conference.
Dr. Gudrun Feuchtner will present groundbreaking research on behalf of the CONFIRM2 investigators during the “Clinical and Investigative Horizons” session on March 31st. The presentation, titled “Artificial Intelligence-based Quantitative Computed Tomography (AI-QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry CONFIRM2,” will highlight the potential of Cleerly’s AI-QCT for measuring disease in women, a group in which coronary artery disease is often underdiagnosed and undertreated. CONFIRM2, with about 50% female participants, is one of the few studies with such diverse representation. The trial population includes 3,500 participants from sites across 11 countries, highlighting the widespread applicability of the results in addressing cardiovascular health disparities.
About Cleerly
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.
